RobertA.BurgerMD
Obstetrics & Gynecology • Philadelphia, PAGynecologic Oncology
Director of Clinical Research and Gynecologic Oncology Fellowship Program, University of Pennsylvania
Dr. Burger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Philadelphia, PA 19104Phone+1 215-662-3318Fax+1 215-349-5680
Education & Training
University of California (Irvine)Fellowship, Gynecologic Oncology, 1992 - 1996
University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1988 - 1992
New York University School of MedicineClass of 1988
Harvard UniversityAB, Biochemistry, Cum Laude, 1980 - 1984
Certifications & Licensure
CA State Medical License 1991 - 2021
PA State Medical License 1991 - 2020
NV State Medical License 1998 - 2003
TX State Medical License 1997 - 2000
Awards, Honors, & Recognition
- Philadelphia Magazine Castle Connolly, 2012-2014
- America's Top Doctors Castle Connolly, 2012-2014
- America's Top Doctors for Cancer Castle Connolly, 2012-2013
- Join now to see all
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
- Join now to see all
Publications & Presentations
PubMed
- 189 citationsRandomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology StudyDmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes
Journal of Clinical Oncology. 2020-04-10 - 77 citationsRandomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial ...Holly H. Gallion, Virginia L. Brunetto, Michael L. Cibull, Samuel S. Lentz, Gary Reid
Journal of Clinical Oncology. 2003-10-15 - 1473 citationsIncorporation of Bevacizumab in the Primary Treatment of Ovarian CancerRobert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk
The New England Journal of Medicine. 2011-12-28
Grant Support
- Angiogenesis Targeted Therapeutics Of Ovarian CancerNational Cancer Institute2001–2006
- Core--Clinical Research OfficeNational Cancer Institute2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
